For General Information, page-3123

Global Duchenne Muscular Dystrophy Drugs Market to Reach $18.1 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Duchenne Muscular Dystrophy Drugs estimated at US$1.1 Billion in the year 2022, is projected to reach a revised size of US$18.1 Billion by 2030, growing at a CAGR of 42.5% over the analysis period 2022-2030. Exon Skipping, one of the segments analyzed in the report, is projected to record a 48.6% CAGR and reach US$12.8 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Steroid Therapy segment is readjusted to a revised 32% CAGR for the next 8-year period.

The U.S. Market is Estimated at $312.7 Million, While China is Forecast to Grow at 40% CAGR

The Duchenne Muscular Dystrophy Drugs market in the U.S. is estimated at US$312.7 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$2.8 Billion by the year 2030 trailing a CAGR of 40% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 39.3% and 35.7% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 28.5% CAGR.


Did Dr. James Garner recently mention about China and Japan??